title: Genetic variations in interleukin-6 polymorphism and the association with susceptibility and overall survival of osteosarcoma.
abstract: Interleukin-6 (IL-6), a central proinflammatory cytokine, may be involved in both development and progression of many human malignancies. Therefore, we aimed to evaluate any associations of IL-6 gene polymorphisms with susceptibility and overall survival of osteosarcoma in a Chinese population. A total of 412 subjects, including 206 patients with osteosarcoma and 206 healthy controls, were recruited and were assessed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in this study. Significant differences of genotype distribution were observed between osteosarcoma cases and controls at the IL-6 -174 G/C genotypes. Compared with the homozygote GG, the heterozygous GC genotype was associated with significantly increased risk for osteosarcoma (odds ratio [OR] = 1.58, 95 % confidence interval [CI] = 1.13-3.05, p = 0.028); the CC genotype was associated with increased risk for osteosarcoma (OR = 1.57, 95 % CI = 1.21-3.26, p = 0.022). Moreover, the genotype CC of IL-6 -174 G/C carried a higher risk of osteosarcoma metastasis and later Enneking stages, compared with the GG genotype. The IL-6 -174 G/C genotype was associated with risk for development and metastasis of osteosarcoma in Chinese Han population.
authors.affiliation: Department of Orthopedics, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China. qiylhb2323@sina.com.
authors.forename: Yunlong
authors.initials: Y
authors.lastname: Qi
authors.affiliation: Department of Orthopedics, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
authors.forename: Chengbin
authors.initials: C
authors.lastname: Zhao
authors.affiliation: Department of Orthopedics, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
authors.forename: Hongxi
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Immunology, The Institute of Medical Oncology, Harbin Medical University, Harbin, 150001, China.
authors.forename: Benning
authors.initials: B
authors.lastname: Zhang
authors.affiliation: Department of Immunology, The Institute of Medical Oncology, Harbin Medical University, Harbin, 150001, China.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Tada
authors.affiliation: Kudan Clinic, The Institute of Medical Oncology, Kudan, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Abe
authors.affiliation: Department of Immunology, The Institute of Medical Oncology, Kudan, Japan.
authors.forename: Midori
authors.initials: M
authors.lastname: Tada
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000235:genetics*; D001859:Bone Neoplasms / Q000235:genetics / Q000401:mortality* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics*; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D012516:Osteosarcoma / Q000235:genetics / Q000401:mortality* / Q000556:secondary; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; C508600:IL6 protein, human; D015850:Interleukin-6
keywords: IL-6; Osteosarcoma; Single-nucleotide polymorphism; Susceptibility
references.citation: Lancet. 2013 Sep 7;382(9895):889-99
references.pmid: 23618600
references.citation: Cancer Res. 2012 Apr 1;72(7):1865-77
references.pmid: 22350417
references.citation: Asian Pac J Cancer Prev. 2013;14(6):3677-80
references.pmid: 23886164
references.citation: Int J Cancer. 1996 Dec 11;68(6):759-65
references.pmid: 8980180
references.citation: Pak J Med Sci. 2013 Sep;29(5):1182-6
references.pmid: 24353716
references.citation: Immunome Res. 2013 Aug 12;9(62):16535
references.pmid: 24078831
references.citation: Tumour Biol. 2015 May;36(5):3679-84
references.pmid: 25566963
references.citation: Biomed Rep. 2014 Sep;2(5):637-643
references.pmid: 25054003
references.citation: Pol Arch Med Wewn. 2007 May-Jun;117(5-6):247-51
references.pmid: 18030875
references.citation: Int J Biol Markers. 2006 Oct-Dec;21(4):246-50
references.pmid: 17177164
references.citation: BMC Vet Res. 2012 May 15;8:56
references.pmid: 22587466
references.citation: Asian Pac J Cancer Prev. 2014;15(17):7357-62
references.pmid: 25227842
references.citation: Expert Rev Anticancer Ther. 2006 Jul;6(7):1075-85
references.pmid: 16831079
references.citation: Cytokine. 2010 Apr;50(1):30-6
references.pmid: 20044268
references.citation: Clin Immunol. 2008 Aug;128(2):199-204
references.pmid: 18502691
references.citation: Cancer Res. 2003 Jun 15;63(12):3066-8
references.pmid: 12810629
references.citation: World J Gastroenterol. 2013 Apr 28;19(16):2449-55
references.pmid: 23674845
references.citation: Cancer Res. 2003 Jul 1;63(13):3560-6
references.pmid: 12839942
references.citation: Oncologist. 2004;9(4):422-41
references.pmid: 15266096
references.citation: J Cell Biochem. 2005 Jun 1;95(3):497-505
references.pmid: 15838876
references.citation: Eur J Cancer. 2010 May;46(7):1223-31
references.pmid: 20335016